FDA approves Intra-Cellullar's schizophrenia drug, shares soar 85%

Intra-Cellular Therapies Inc said on Monday its lead drug to treat schizophrenia in adults has received approval from the U.S. Food and Drug Administration, sending its shares soaring 85%.

from Reuters: Health News https://ift.tt/2sTGai4